Nuvation Bio: Why Ibtrozi's 6x Adoption Rate Changes The Thesis (Rating Upgrade)

Stephen Ayers9.54K FollowersFollow5ShareSavePlay(8min)CommentsSummaryNuvation Bio is upgraded from Sell to Hold, reflecting improved IBTROZI adoption but growing competitive risks.IBTROZI's rapid uptake in ROS1+ NSCLC establishes a valuation floor, but Nuvalent's zidesamtinib could erode its market share by 2027.Safusidenib's shift to high-grade gliomas avoids direct competition but limits total addressable market and near-term valuation impact.Current valuation appears modestly overvalued at $4–$5/share, with pipeline attrition and competitive threats tempering long-term enthusiasm. Vladislav Stepanov/iStock via Getty Images Overview My last evaluation of Nuvation Bio (NUVB) was in August 2025. While I acknowledged IBTROZI’s appeal in ROS1+ NSCLC, relative to other TKIs like AUGTYRO and ROZLYTREK, I also noted that it’s a small market and competition—in the form of Nuvalent’s (This article was written byStephen Ayers9.54K FollowersFollowRN/MBA with a focus on Biotech, Pharma, and Tech sectors.Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. This article is intended to provide informational content and should not be viewed as an exhaustive analysis of the featured company. It should not be interpreted as personalized investment advice with regard to "Buy/Sell/Hold/Short/Long" recommendations. The predictions and opinions presented are based on the author's analysis and reflect a probabilistic approach, not absolute certainty. Efforts have been made to ensure the information's accuracy, but inadvertent errors may occur. Readers are advised to independently verify the information and conduct their own research. Investing in stocks involves inherent volatility, risk, and speculative elements. Before making any investment decisions, it is crucial for readers to conduct thorough research and assess their financial circumstances. The author is not liable for any financial losses incurred as a result of using or relying on the content of this article.Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.